The development of nanoparticle (NP)-based delivery systems for precision targeting of HIF-1α inhibitors to LN-resident macrophages may represent a promising therapeutic strategy to enhance T cell tumor infiltration and overcome resistance to ICIs. Here, HIF1A is linked to neoplasm.